Heterogeneity in recent‐onset type 1 diabetes – a clinical trial perspective

Type 1 diabetes (T1D) TrialNet is a National Institutes of Health‐sponsored clinical trial network aimed at altering the disease course of T1D. The purpose of this study is to evaluate age‐dependent heterogeneity in clinical, metabolic and immunologic characteristics of individuals with recent‐onset T1D, to identify cohorts of interest and to aid in planning of future studies.

[1]  W. Scherbaum,et al.  Age‐dependent decline of β‐cell function in type 1 diabetes after diagnosis: a multi‐centre longitudinal study , 2014, Diabetes, obesity & metabolism.

[2]  J. Lachin,et al.  Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial , 2014, Diabetes.

[3]  Darrell M. Wilson,et al.  B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results , 2014, Diabetes Care.

[4]  Darrell M. Wilson,et al.  Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials , 2013, The Lancet.

[5]  P. Marchetti,et al.  Reduction of Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes , 2013, Diabetes.

[6]  Å. Lernmark,et al.  Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. , 2013, Diabetes research and clinical practice.

[7]  M. Redondo,et al.  Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes , 2012, Pediatric diabetes.

[8]  C. Beam,et al.  Fall in C-Peptide During First 2 Years From Diagnosis , 2012, Diabetes.

[9]  Juan Pedro López,et al.  GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. , 2012, The New England journal of medicine.

[10]  Darrell M. Wilson,et al.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[11]  Darrell M. Wilson,et al.  Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes , 2010, Diabetes Care.

[12]  Darrell M. Wilson,et al.  Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes Running title: MMF and DZB in New Onset T1D , 2010 .

[13]  M. Steffes,et al.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. , 2003, Diabetes care.

[14]  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.